1. Home
  2. PLMR vs PBLS Comparison

PLMR vs PBLS Comparison

Compare PLMR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palomar Holdings Inc.

PLMR

Palomar Holdings Inc.

HOLD

Current Price

$123.04

Market Cap

3.4B

Sector

Finance

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$32.57

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLMR
PBLS
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.6B
IPO Year
2019
2026

Fundamental Metrics

Financial Performance
Metric
PLMR
PBLS
Price
$123.04
$32.57
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $153.60
N/A
AVG Volume (30 Days)
180.6K
★ 704.8K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 60.04
N/A
EPS
★ 3.51
N/A
Revenue
★ $875,967,000.00
N/A
Revenue This Year
$192.25
N/A
Revenue Next Year
$19.34
N/A
P/E Ratio
$35.36
★ N/A
Revenue Growth
★ 58.16
N/A
52 Week Low
$100.81
$25.56
52 Week High
$147.62
$42.49

Technical Indicators

Market Signals
Indicator
PLMR
PBLS
Relative Strength Index (RSI) 33.96 39.32
Support Level $116.69 $26.42
Resistance Level $125.81 $33.65
Average True Range (ATR) 4.01 3.14
MACD -1.55 -0.93
Stochastic Oscillator 9.84 21.56

Price Performance

Historical Comparison
PLMR
PBLS

About PLMR Palomar Holdings Inc.

Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: